MolDX: Oncotype DX Genomic Prostate Score Coding and Billing

The MolDX: Oncotype DX® Genomic Prostate Score Coding and Billing Article has been created and published for notice under contract numbers:  01111 (CA), 01211 (HI and Territories), 01311 (NV) and 01911 (CA, HI & Territories).

Summary of Article: The Oncotype DX® Genomic Prostate Score (Genomic Health®) is a covered test for use in very low risk, low risk, and favorable intermediate risk prostate cancer. The CPT code to bill for this service on or after 01/01/19 is 0047U. The article will also be linked to the Local Coverage Determination (LCD) L36364, MolDX: Genomic Health™ Oncotype DX® Prostate Cancer Assay.

  • 0047U - Oncology (prostate), mRNA, gene expression profiling by real-time RT-PCR of 17 genes (12 content and 5 housekeeping), utilizing formalin-fixed paraffin-embedded tissue, algorithm reported as a risk score.

Effective Date: January 1, 2019

View the locally hosted MolDX Medicare Coverage Article.

  • Go to Molecular Diagnostic Services (MolDX) webpage
    • The End User Agreement for Providers will appear if you have not recently visited the website. Select "Accept" (if necessary)
  • Locate and select above listed Medicare Coverage Article from "Covered Tests" or "Excluded Tests" webpage

View a complete list of Noridian coverage articles.

  • Go to Noridian Medicare Coverage Articles webpage
  • Scroll to bottom of page
  • Select state/contract link of interest from applicable Active, Future, or Retired Articles column
    • Link will redirect you to CMS MCD
  • In CMS MCD, select corresponding article title to view a comprehensive revision history for this article

Last Updated Mar 14, 2019